HR Execs on the Move


 
Today`s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion
  • www.merck.com
  • 2000 Galloping Hill Road
    Kenilworth, NJ USA 07033
  • Phone: 908.740.4000

Executives

Name Title Contact Details
Frederic-Andre Vennat
Executive Director, Program Management Office Lead, Human Health Profile
Jacob Langbein
Director, Global Marketing Profile
Greg Elwood
Associate Director, US Payer Marketing Profile
Ali Guerrieri
Associate Director Consumer Marketing Profile
Anoop Kumar
Director Financial Systems, Life Science Profile

Similar Companies

Advanced Care Scripts

Advanced Care Scripts is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pierre Fabre Laboratories

Pierre Fabre Laboratories is a Saint-Bruno, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

St. Joseph Children's Home

We providing a continuum of care through our three programs: Foster Care and Adoption Program, Residential Treatment Program, and Child Development Center.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.